Glycomet: Advanced Blood Glucose Control for Diabetes Management
| Product dosage: 500mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 180 | $0.24 | $43.06 (0%) | 🛒 Add to cart |
| 270 | $0.21 | $64.59 $57.08 (12%) | 🛒 Add to cart |
| 360 | $0.20
Best per pill | $86.12 $71.10 (17%) | 🛒 Add to cart |
Similar products
Glycomet is a trusted pharmaceutical formulation containing metformin hydrochloride, designed specifically for the management of type 2 diabetes mellitus. As a first-line oral antidiabetic agent, it effectively reduces hepatic glucose production and improves insulin sensitivity in peripheral tissues. Its well-established efficacy and safety profile make it a cornerstone therapy in diabetes care protocols worldwide. Glycomet is suitable for use as monotherapy or in combination with other glucose-lowering agents, providing clinicians and patients with a reliable option for long-term glycemic control.
Features
- Contains metformin hydrochloride as the active ingredient
- Available in multiple strengths: 500 mg, 850 mg, and 1000 mg film-coated tablets
- Delayed-release and extended-release formulations for tailored dosing
- Manufactured under strict pharmaceutical quality control standards
- Bioequivalent to reference listed drugs
- Packaged in blister strips for stability and ease of use
Benefits
- Effectively lowers both fasting and postprandial blood glucose levels
- Reduces the risk of diabetes-related complications through sustained glycemic control
- Associated with weight neutrality or modest weight loss, unlike some other antidiabetic agents
- May improve lipid profiles and offer cardiovascular protective benefits
- Does not cause hypoglycemia when used as monotherapy
- Cost-effective and widely accessible treatment option
Common use
Glycomet is primarily indicated for the management of type 2 diabetes mellitus in adults and children over 10 years of age. It is used when glycemic control cannot be achieved through diet and exercise alone. The medication may be prescribed as initial monotherapy or in combination with other oral antidiabetic agents or insulin. Off-label uses may include polycystic ovary syndrome (PCOS) management and prevention of diabetes in high-risk individuals, though these applications require careful medical supervision.
Dosage and direction
The initial recommended dose is typically 500 mg once or twice daily, or 850 mg once daily, taken with meals to minimize gastrointestinal side effects. Dosage should be titrated gradually based on glycemic response and tolerability, with usual maintenance doses ranging from 1500 mg to 2000 mg daily divided into two or three doses. The maximum recommended daily dose is 2550 mg for immediate-release formulations and 2000 mg for extended-release formulations. Extended-release tablets should be swallowed whole and not crushed or chewed. Dosage adjustments are necessary in patients with renal impairment, and regular monitoring of renal function is recommended.
Precautions
Before initiating Glycomet therapy, assess renal function through estimation of glomerular filtration rate (eGFR). Use with caution in elderly patients, those with hepatic impairment, or patients consuming alcohol excessively. Monitor vitamin B12 levels periodically during long-term treatment, as metformin may impair B12 absorption. Temporary discontinuation may be necessary before procedures involving iodinated contrast media due to the risk of contrast-induced nephropathy and subsequent lactic acidosis. Educate patients about recognizing symptoms of lactic acidosis, though this adverse effect is rare.
Contraindications
Glycomet is contraindicated in patients with severe renal impairment (eGFR below 30 mL/min/1.73m²) or renal disease. Additional contraindications include acute or chronic metabolic acidosis, including diabetic ketoacidosis; history of hypersensitivity to metformin or any component of the formulation; acute conditions that may alter renal function such as dehydration, severe infection, or shock; and hepatic impairment. The medication should not be used in patients undergoing radiological studies involving intravascular iodinated contrast materials.
Possible side effects
The most common adverse reactions involve the gastrointestinal system, including diarrhea, nausea, vomiting, abdominal discomfort, and anorexia, which often diminish with continued therapy. Other potential side effects include metallic taste, decreased vitamin B12 absorption, and rarely, lactic acidosis—a serious metabolic complication that requires immediate medical attention. Skin reactions such as erythema, pruritus, and urticaria may occur infrequently. Hypoglycemia is uncommon with monotherapy but may occur when used with other glucose-lowering agents.
Drug interaction
Glycomet may interact with several medication classes. Cationic drugs that are eliminated by renal tubular secretion (such as cimetidine, ranitidine, and vancomycin) may increase metformin plasma levels. Alcohol potentiates the effect of metformin on lactate metabolism and increases the risk of lactic acidosis. Concomitant use with iodinated contrast media may increase the risk of acute renal failure. Certain medications like corticosteroids, diuretics, and sympathomimetics may reduce the hypoglycemic effect of metformin. Close monitoring is recommended when combining with other antidiabetic agents due to potential additive effects.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is almost time for the next scheduled dose. In that case, skip the missed dose and resume the regular dosing schedule. Do not double the dose to make up for a missed one. Consistent dosing is important for maintaining stable blood glucose control, so patients should establish routines to minimize missed doses. If multiple doses are missed, contact a healthcare provider for guidance on resuming therapy.
Overdose
Metformin overdose, particularly doses exceeding 10 grams, may lead to lactic acidosis, which is a medical emergency characterized by elevated blood lactate levels, metabolic acidosis, hypothermia, hypotension, and resistant bradyarrhythmias. Hypoglycemia has not been reported with metformin overdose alone but may occur when combined with other antidiabetic agents. Treatment is primarily supportive and includes immediate hospitalization, correction of electrolyte imbalances, hemodialysis to correct acidosis and remove metformin, and monitoring of vital signs and metabolic parameters.
Storage
Store Glycomet tablets at controlled room temperature between 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C to 30°C (59°F to 86°F). Keep the medication in its original container, tightly closed, and protected from light and moisture. Do not store in bathrooms or other damp areas. Keep out of reach of children and pets. Properly discard any expired or unused medication according to local regulations, avoiding flushing down toilets or drainage systems unless specifically instructed.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Glycomet is a prescription medication that should be used only under the supervision of a qualified healthcare professional. Individual response to therapy may vary, and treatment decisions should be based on a comprehensive assessment by a medical practitioner. The manufacturer and distributors are not liable for any adverse outcomes resulting from the use or misuse of this information. Always consult with a healthcare provider before starting, stopping, or changing any medication regimen.
Reviews
Clinical studies and patient reports consistently demonstrate Glycomet’s effectiveness in achieving glycemic targets with a favorable safety profile. Many patients report improved HbA1c levels within 3-6 months of initiation. Healthcare providers appreciate its predictable pharmacokinetics and well-documented efficacy in diverse patient populations. Some users note initial gastrointestinal discomfort that typically resolves with continued use. The extended-release formulation receives particular praise for improved tolerability and convenience. Overall, Glycomet maintains high satisfaction ratings among both prescribers and patients for its role in comprehensive diabetes management.